Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of INCB086550 (Oral PD-L1 Inhibitor) in Participants Who Are Immune Checkpoint Inhibitor-Naïve With Selected Solid Tumors

NCT04629339 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT04629339
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04629339 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of INCB086550 (Oral PD-L1 Inhibitor) in Participants Who Are Immune Checkpoint Inhibitor-Naïve With Selected Solid Tumors
Lead sponsor
Incyte Corporation
Phase
Phase 2
Overall status
Terminated
Start date
September 2, 2021
Completion date
March 26, 2024
Enrollment
16 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma, melanoma, non small cell lung cancer, renal cell carcinoma, urothelial cancer